Skip to main content

Ruthenium-based photoactivated chemotherapy against eye cancer

Project description

Photoactivated chemotherapy for the treatment of uveal melanoma

Uveal melanoma (UM) is a rare malignancy of the eye. Current treatment options do not always preserve vision or the eye and often result in patient death from metastasis to the liver. Photoactivated chemotherapy (PACT) is an innovative therapeutic solution that involves photosensitive compounds that can kill cancer cells selectively under the action of light. The EU-funded Ru4EYE project aims to develop a pre-clinical proof of concept that ruthenium (Ru)-based PACT compounds can be used to treat uveal melanoma. The success of the project will not only provide pre-clinical proof-of-concept that PACT may become an effective treatment option for uveal melanoma patients, but also accelerate the adoption of Ru-based PACT in the treatment of other diseases as well.

Host institution

UNIVERSITEIT LEIDEN
Net EU contribution
€ 150 000,00
Address
Rapenburg 70
2311 EZ Leiden
Netherlands

See on map

Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Activity type
Higher or Secondary Education Establishments
Other funding
No data

Beneficiaries (1)

UNIVERSITEIT LEIDEN
Netherlands
Net EU contribution
€ 150 000,00
Address
Rapenburg 70
2311 EZ Leiden

See on map

Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Activity type
Higher or Secondary Education Establishments
Other funding
No data